Cogent Biosciences Inc
COGT
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.24B
Close$
$0.87
97.7% downside
Current Fair Value
97.7% downsideOvervalued by 97.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.24 Billion |
|---|---|
| Enterprise Value | $7.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.55 |
| Beta | 0.34 |
| Outstanding Shares | 67,414,000 |
Return
| Return on Equity | -70.85% |
|---|---|
| Return on Assets | -45.20% |
| Return on Invested Capital | -50.18% |
Valuation & Multiples
| P/E Ratio | -13.76 |
|---|---|
| PEG | -44.24 |
| Price to Sales | - |
| Price to Book Ratio | 5.33 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -18.78 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
$1,000
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-0.57
Average shareholder expectationRevenue Estimate
$750,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 59.30% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 55.85%▼ 219.79% |
|---|---|
| Total Invested | $1.46B▼ 79.68% |
| Investors Holding | 94▼ 223.00% |
ESG Score
No data
About Cogent Biosciences Inc
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently ...